Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | CCR2 | P41597 | 2/20 | 0.48 |
| ▸ | HTR1D | P28221 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR1E | P28566 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.45 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.44 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.44 |
| ▸ | ITGAL | P20701 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | GFRA3 | O60609 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19051483 | 0.86 | SLC6A5 (0.53) | SLC6A5CCR2HTR1DHTR2CHTR1E | |
| SCHEMBL16551861 | 0.86 | CYP3A4 (0.52) | SLC6A5CCR2HTR1DHTR2CHTR1E | |
| SCHEMBL18381307 | 0.86 | CYP3A4 (0.52) | SLC6A5CCR2HTR1DHTR2CHTR1E | |
| SCHEMBL19051460 | 0.84 | SLC15A2 (0.54) | SLC6A5CCR2HTR1DHTR2CHTR1E | |
| SCHEMBL29002721 | 0.84 | HTR1D (0.48) | SLC6A5CCR2HTR1DHTR2CHTR1E | |
| SCHEMBL27926539 | 0.83 | SLC6A5 (0.70) | SLC6A5CCR2HRH3 | |
| SCHEMBL5808674 | 0.82 | HTR1D (0.51) | HTR1DHTR2CHTR1EHTR2BHTR2A | |
| SCHEMBL7598348 | 0.82 | ITGB2 (0.55) | SLC6A5HTR1DHTR2CHTR1EHTR2B | |
| SCHEMBL28778341 | 0.81 | SLC6A5 (0.46) | SLC6A5CCR2HTR1DHTR2CHTR1E | |
| SCHEMBL29272055 | 0.81 | SLC6A5 (0.63) | SLC6A5CCR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183318-A1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183318-A1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES | ACE, ACE2, MCTS1 | SLC6A5 3373/4885CCR2 318/4885HTR1D 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.